Dr. Fabio Almeida leads teams at Phoenix Molecular Imaging in Phoenix and Southwest PET/CT Institute in Yuma Arizona. Through support for research trials we offer our patients the ability to take part in the continued progress of medicine and science.

Diagnostic imaging techniques and treatments we currently support:

Description: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse

Summary: The goal of this study is improved imaging of prostate cancer by positron emission tomography (PET) with use of the radiopharmaceutical C-11 Acetate, utilizing state-of-the-art PET/CT camera technology and processing algorithms. A successful effort will lead to more accurate diagnosis of recurrence in patients with prostate cancer to allow for early directed therapy. This study is designed to generate data to add to the understanding of the effectiveness of C-11 Acetate, focusing on patients with recurrent or persistent disease after prostatectomy or radiation therapy. Learn More From National Cancer Institute >>


Description: C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Summary: Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments. Learn More From National Cancer Institute >>


Description: A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)

Summary: This study is a phase III double blind, placebo controlled, study with a randomization allocation ratio of 1:1 (radium-223 dichloride plus abiraterone acetate plus prednisone: placebo plus abiraterone acetate plus prednisone).The study period will consist of screening/randomization, treatment, active follow-up with clinic visits, active follow-up without clinic visits, and long-term follow-up phases. In this study, subjects will receive study treatment (radium-223 dichloride or placebo in addition to abiraterone acetate plus prednisone for the first 6 cycles followed by abiraterone acetate plus prednisone thereafter). Contact: Elisa Blackwell 602.331.1771 for more information. Learn More From NIH >>